2. Academic Validation
  3. Mechanistic study of N-acetyltransferase 10 deficiency enhancing olaparib sensitivity in triple negative breast cancer by inhibiting RAD51 N4-acetylcytidine modification

Mechanistic study of N-acetyltransferase 10 deficiency enhancing olaparib sensitivity in triple negative breast cancer by inhibiting RAD51 N4-acetylcytidine modification

  • iScience. 2025 Jun 9;28(7):112860. doi: 10.1016/j.isci.2025.112860.
Hui Li 1 2 3,  Hao Wu 1 4 3,  Siwei Li 1 2 3,  Qin Wang 1 4 3,  Guozheng Li 1 2 3,  Xin Ma 1 2 3,  Yajie Gong 1 2 3,  Yijun Chu 1 2 3,  Shengye Jin 1 2 3,  Xi Chen 5,  Xianyu Zhang 1 2 3,  Da Pang 1 2 3
Affiliations

Affiliations

  • 1 Heilongjiang Clinical Research Center for Breast Cancer, Harbin Medical University Cancer Hospital, Harbin 150081, China.
  • 2 Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China.
  • 3 Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin 150081, China.
  • 4 Key Laboratory of Tumor Biotherapy of Heilongjiang Province, Harbin Medical University Cancer Hospital, Harbin 150081, China.
  • 5 Department of Breast Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China.
PMID: 40606759 DOI: 10.1016/j.isci.2025.112860
Abstract

The treatment of triple-negative breast Cancer (TNBC) is challenging due to the lack of common treatment targets, making standard hormonal and targeted therapies ineffective. While PARP inhibitors are promising for TNBC, they are only effective in homologous recombination (HR)-deficient cells with BRCA1/2 mutations. Nevertheless, resistance to PARP inhibitors often develops. Thus, it is imperative to identify strategies or targets that can enhance the efficacy of PARP inhibitors. In this study, we demonstrated that TNBC cells lacking N-acetyltransferase 10 (NAT10) exhibited greater sensitivity to olaparib and extensive DNA double-strand breaks (DSBs). Mechanistically, NAT10 upregulates the N4-acetylcytidine (ac4C) modification of RAD51 mRNA, enhancing its stability and increasing RAD51 expression. Remarkably, the combination of olaparib and remodelin, an inhibitor of NAT10, induced robust anti-tumor effects in vitro and in vivo by promoting DSBs. Our findings illuminate a potential therapeutic strategy targeting NAT10 to enhance olaparib efficacy in TNBC.

Keywords

Cancer; Cell biology; Molecular biology.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z